TScan Therapeutics Inc (TCRX)

[crazy horse 0]

S-3/A Filings

https://www.otcmarkets.com/stock/TCRX/disclosure

[crazy horse 0]

Holy COW that is some presentation

TCRX May Corporate Presentation is a must read for serious investors

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

The whole presentation spells out the potential from oncology - autoimmune - infectious disease

Of course, it will be the trial data that will confirm whether the TCR-T approach is indeed successful.

Thank you.

[crazy horse 0]

Will listen to that Presentation if I am allowed in

TCRX May Presentation (it has been posted on TCRX website)

Awesome presentation coming up at ASGCT imo, - highly, highly professional, imo.
Gonna turn some heads on Wednesday, imo.

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

Spot on again bro, Slide #7

TScan Therapeutics, Inc.
Steady value-generating data flow across clinical programs
Heme Program
Enroll patients in all 3 arms of trial
Safety and biomarker data at ASGCT

[The Night Stalker]

agreed

[FACT-MASTER]

TCRX May Corporate Presentation is a must read for serious investors

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

The whole presentation spells out the potential from oncology - autoimmune - infectious disease

Of course, it will be the trial data that will confirm whether the TCR-T approach is indeed successful.

Thank you.

[FACT-MASTER]

TCRX May Presentation (it has been posted on TCRX website)

Awesome presentation coming up at ASGCT imo, - highly, highly professional, imo.
Gonna turn some heads on Wednesday, imo.

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

Spot on again bro, Slide #7

TScan Therapeutics, Inc.
Steady value-generating data flow across clinical programs
Heme Program
Enroll patients in all 3 arms of trial
Safety and biomarker data at ASGCT

[FACT-MASTER]

That looks like potential sales by David Southwell who stepped down on March 31/23.

https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-announces-ceo-transition

Some shares bought on the open market and some for compensation, looks like the holding period requirement has been met.

https://www.upcounsel.com/rule-144

[crazy horse 0]

FORM 144 Title of the Class of Securities To Be Sold

https://www.otcmarkets.com/filing/html?id=16656101&guid=Hiu-kFUYuTxmB3h

#1 Common
Charles Schwab Company
3000 Schwab Way
Westlake
TEXAS
76262
85,911 $346,221.00 19,480,729 05/15/2023
Nasdaq

[crazy horse 0]

A Buyout is not out of the Question

(i'm not 100% sure, but TCRX Technology may be a perfect fit for Amgen Oncology and there could be more to the recent Amgen collaboration then Cohns disease, in my optimistic opinion.)

On another topic, it appears that Amgen Oncology does not currently have a TCR-T Modality category in their pipeline.

see here:

https://www.amgenoncology.com/clinical-trial-finder.html#modality

then click on Oncolytic Immunotherapy

https://www.amgenoncology.com/modalities/oncolyticimmunotherapy.html

Physicians have long observed that certain viruses can slow the progression of cancer. Oncolytic immunotherapy aims to harness this potential by using genetically modified viruses to target tumors in several important and complementary ways.1

By deleting certain genes, viruses can be reprogrammed to replicate in tumor cells but not in normal cells. This selective viral replication causes the tumor cells to lyse—releasing tumor-specific antigens.1 The virus can also be modified to produce human GM-CSF, signaling dendritic cells to the site of the lysed tumors where they encounter tumor antigens—generating a broad immunotherapeutic response that can help cytotoxic T cells to recognize and attack distant metastases throughout the body.

(i'm not 100% sure, but TCRX Technology may be a perfect fit for Amgen Oncology and there could be more to the recent Amgen collaboration then Cohns disease, in my optimistic opinion.)

Click on Technology https://www.tscan.com/

[crazy horse 0]

And one of the Directors of Bakers Bros sits on the Board very positive

That's a nice update, thanks for posting that. Impressive institutional involvement, imo.

The category of TCR-T, is still relatively new imo, with little in vivo data available to date.

For information purposes, Kimmtrack was the first FDA approved TCR-T in January of 2022 and there is an interesting read here :

https://acgtfoundation.org/news/explaining-t-cell-receptor-therapy-for-cancer/

[FACT-MASTER]

On another topic, it appears that Amgen Oncology does not currently have a TCR-T Modality category in their pipeline.

see here:

https://www.amgenoncology.com/clinical-trial-finder.html#modality

then click on Oncolytic Immunotherapy

https://www.amgenoncology.com/modalities/oncolyticimmunotherapy.html

Physicians have long observed that certain viruses can slow the progression of cancer. Oncolytic immunotherapy aims to harness this potential by using genetically modified viruses to target tumors in several important and complementary ways.1

By deleting certain genes, viruses can be reprogrammed to replicate in tumor cells but not in normal cells. This selective viral replication causes the tumor cells to lyse—releasing tumor-specific antigens.1 The virus can also be modified to produce human GM-CSF, signaling dendritic cells to the site of the lysed tumors where they encounter tumor antigens—generating a broad immunotherapeutic response that can help cytotoxic T cells to recognize and attack distant metastases throughout the body.

(i'm not 100% sure, but TCRX Technology may be a perfect fit for Amgen Oncology and there could be more to the recent Amgen collaboration then Cohns disease, in my optimistic opinion.)

Click on Technology https://www.tscan.com/

[FACT-MASTER]

That's a nice update, thanks for posting that. Impressive institutional involvement, imo.

The category of TCR-T, is still relatively new imo, with little in vivo data available to date.

For information purposes, Kimmtrack was the first FDA approved TCR-T in January of 2022 and there is an interesting read here :

https://acgtfoundation.org/news/explaining-t-cell-receptor-therapy-for-cancer/

[crazy horse 0]

TScan is a clinical-stage biopharmaceutical company dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system.

Very impressive Management and Board Members

https://www.tscan.com/

[crazy horse 0]

TCRX outstanding shares of 24,225,954,

As of March 31, 2023, the Company had issued and outstanding shares of 24,225,954, which consists of 19,480,729 shares of voting common stock and 4,745,225 shares of non-voting common stock.

https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-reports-first-quarter-2023-financial-results/?auth_token=2aba5703-2c15-47d3-8454-aae1810f335b

[crazy horse 0]

BOARD OF DIRECTORS TCRX BAKER BROS. ADVISORS LP Stephen Biggar, M.D., Ph.D

Stephen Biggar, M.D., Ph.D., has served as a member of our board of directors since March 2021. Dr. Biggar is a partner at Baker Bros. Advisors LP, a biotechnology-focused investment advisor, a firm he joined in April 2000. Dr. Biggar serves on the boards of directors of Kiniksa Pharmaceuticals, Ltd., and Acadia Pharmaceuticals Inc.

Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University and received a B.S. in Genetics from the University of Rochester.

.https://www.tscan.com/leader/stephen-biggar-m-d-ph-d/

[crazy horse 0]

TCRX institution holders

[FACT-MASTER]

TCRX: Novartis collaboration news (old news)

https://www.sec.gov/Archives/edgar/data/1783328/000095012321003678/filename3.htm

https://www.biospace.com/article/tscan-and-novartis-partner-to-develop-immune-therapies-for-solid-tumors/

https://www.biopharminternational.com/view/tscan-therapeutics-novartis-collaborate-t-cell-receptor-therapies

Collaboration period ended March 31/23 = 180 day countdown for Novartis to exercise licensing (Sept.28/23 deadline to advise on intent to license/Tscan notice of intent to license to third party)

[FACT-MASTER]

Novartis Collaboration:

https://ih.advfn.com/stock-market/NASDAQ/tscan-therapeutics-TCRX/stock-news/91014982/quarterly-report-10-q

"The Company will continue to assess the probability of milestone
payments throughout the180-day right of first negotiation period".

What insights are available into what TCRX might have discovered during the Novartis collaboration period, and to whom would these TCR targets be of concern/value to? And to what monetary value are such TCR discoveries worth/to Novartis/others.

Deadline for the 180-day right of first negotiation period, in and around September 28 by my count.

Given the Amgen news came out, out of nowhere, so to, could news on licensing/Novartis come out anytime to Sept.28/23.

[crazy horse 0]

TCRX Look at the pipelines and partners in $AMGN and $NVS. One of a kind!!!

[crazy horse 0]

May 17 EVENT, They halted TCRX IMO for Shorts to cover

TScan Therapeutics ASGCT Event: Highlights from Phase 1 Umbrella Trial of TSC-100 and TSC-101

https://lifescievents.com/event/tscan/

[ttottip]

Insiders know something. If so, the price will plunge drastically.

[ttottip]

Insiders know something.

[Gizzer211]

Offering?

[IOUBLOKE1]

halted

[crazy horse 0]

$TCRX TScan Therapeutics ASGCT Event: Highlights from Phase 1 Umbrella Trial of TSC-100 and TSC-101

https://lifescievents.com/event/tscan/

[Jess070283]

Adding. This is my biggest swinger into double digits!$$$

[dinogreeves]

This is buy, buy and hold: Main reason why I am here is Baker Bros.

[crazy horse 0]

TCRX Analysts have set a mean price target of 10.71. This target is 138% above the current price.

TCRX was analyzed by 11 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about TCRX.

In the previous month the buy percentage consensus was at a similar level.
TCRX was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.

2023-05-11 HC Wainwright & Co. Reiterate Buy -> Buy

https://www.chartmill.com/stock/quote/TCRX/analyst-ratings?utm_source=stocktwits&utm_medium=ANALYST&utm_content=TCRX&utm_campaign=social_tracking

[crazy horse 0]

TScan Therapeutics Inc "We're excited to apply our target discovery platform to the autoimmunity space," said Gavin MacBeath, Ph.D., acting chief executive officer and chief scientific and operating officer at TScan. "Our TargetScan platform, which we have now extended to identify MHC class II targets of CD4+ T cells, is well-suited for the discovery of antigens targeted by the immune system in inflammatory bowel disease. We look forward to developing the value of our platform both in this partnership with Amgen and in other autoimmune diseases."

Inflammatory bowel disease (IBD) is a term for two conditions – Crohn's disease and ulcerative colitis – that are characterized by chronic inflammation of the gastrointestinal tract.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2022, Amgen was named one of the "World's Best Employers" by Forbes and one of "America's 100 Most Sustainable Companies" by Barron's.

For more information, visit Amgen.com and follow us on Twitter, LinkedIn, Instagram, TikTok and YouTube.

About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company's lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company's repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.

https://www.prnewswire.com/news-releases/amgen-and-tscan-therapeutics-announce-collaboration-to-identify-novel-targets-in-crohns-disease-301818552.html

Multi-year partnership with AMGN https://www.prnewswire.com/news-releases/amgen-and-tscan-therapeutics-announce-collaboration-to-identify-novel-targets-in-crohns-disease-301818552.html

Per the terms, TCRX will receive $30M upfront in addition to preclinical, clinical, regulatory, and commercial milestones worth over $500M and tiered single-digit royalties. "TScan's platform provides a best-in-class approach to identify non-conventional drug targets to enable the development of potential first-in-class therapeutics to address unmet medical needs," Raymond Deshaies, AMGN's SVP of Global Research, said.

[crazy horse 0]

Short Vol 2023-05-10 8,496,778 14,636,290 58%

The short sale volume percent (not short interest) for stock ticker TCRX is 58% on May 10, 2023. The short sale volume is 8,496,778. The total volume is 14,636,290.

http://shortvolumes.com/?t=tcrx

[Jess070283]

I smell a squeeze soon…

[crazy horse 0]

TScan Therapeutics, Inc. - 10Q - Quarterly Report - May 10, 2023

https://www.otcmarkets.com/filing/html?id=16638015&guid=kOu-kKnUE8dfJth

[FACT-MASTER]

"I agree, but we might have to wait for a filing."

Correct, from the 10-Q (March 31/23)


Novartis


In
March 2020,
the Company entered into a Collaboration and License Agreement (the
Novartis Agreement) with Novartis Institutes For Biomedical
Research, Inc. (Novartis) to collaborate on their research efforts
to discover and develop novel TCR-T therapies. At the inception
date of the Novartis Agreement, Novartis or its affiliates held an
ownership interest of more than
10%
in the Company, and at
March 31, 2023,
Novartis held less than
10%
of the common shares outstanding. Under the Novartis Agreement, the
Company will identify and characterize TCRs in accordance with a
research plan and transfer data arising from the research plan.
Novartis will have the option to license and develop TCRs for up to
three novel targets identified in performance of the collaboration
during the collaboration period of the Novartis Agreement. Novartis
will also have rights of first negotiation for certain additional
targets and TCRs identified in performance of the collaboration
during a defined collaboration period of the Novartis Agreement and
for
180 days
after such collaboration period ends (which collaboration period
ended in March 2023). If during such
180-day
right of first negotiation period, the Company notifies Novartis of
the Company’s intent to grant a third party a license to a target
or TCR identified in the collaboration, then Novartis may obtain
the exclusive right to negotiate a license to such target or TCR
for an additional 270 days by providing the Company with a term
sheet to license such target or TCR within 90 days of the Company’s
notice of such intent. The Novartis Agreement provides that the
Company will pay an upfront fee of $20.0
million, research funding totaling $10.0
million and potential milestone payments contingent on clinical,
regulatory and sales success. In addition to payments upon
achievement of certain clinical and regulatory milestones, Novartis
will pay the Company mid-single to low double-digit royalties on
net sales for each product directed to a target licensed by
Novartis. After the end of the collaboration period and the
expiration of Novartis’ first right of negotiation, the Company is
free to develop TCRs against targets not licensed by
Novartis.


The Company concluded that Novartis meets the definition of a
customer, as the Company is delivering research and development
activities and know-how rights. The Company identified performance
obligations for research and development activities, data reporting
and participation in joint steering and research committees. The
Company determined there is a single performance obligation due to
the services being highly interrelated and are therefore not
distinct in the context of the contract. The Company combined the
pre-option research services and data reporting into a single
performance obligation. Novartis has an exclusive option to obtain
a commercial license for up to
three
Targets (as defined in the Novartis Agreement) to pursue further
development and commercialization of the respective Target.
Pursuant to the Novartis Agreement, the option for Novartis to
license, develop, and commercialize Targets is not a performance
obligation at the outset of the Novartis Agreement as it is a
customer option that does not represent a material
right.


The Company looked to the promises in the arrangement to determine
the method of recognition that best coincided with the pattern of
delivery. The Company concluded that the performance of the
research services over the expected research term was the
predominant promise within the performance obligation. The Company
recognized the revenue associated with the performance obligation
using the input method, according to the actual costs incurred as a
percentage of total expected costs to complete the research
services. As costs were incurred, the Company recognized revenue
over time.


The Company determined that the $20.0
million upfront payment, together with the $10.0
million of estimated research costs to be reimbursed by Novartis,
to be the entirety of the consideration to be included in the
transaction price as of the outset of the arrangement. The
potential milestone payments that the Company is eligible to
receive were excluded from the transaction price, as all milestone
amounts were fully constrained based on the assessed probability of
achievement. At this time, the Company has recognized all
consideration in the contract as the performance obligations were
satisfied as of March 31, 2023 and the collaboration period ended.
The Company will continue to assess the probability of milestone
payments throughout the
180-day right of first negotiation period.


The Company recognized $5.8
million and $3.0
million of revenue associated with the Novartis Agreement based on
performance completed during that period for the
three months ended March 31, 2023 and 2022, respectively.
Additionally, the Company incurred $1.9
million and $1.0
million of costs associated with the Novartis Agreement that were
recorded within research and development expenses in the statements
of operations for the
three months ended March 31, 2023 and 2022, respectively. Finally,
as of March 31, 2023,
the Company had
no
deferred revenue as all performance obligations were
satisfied.

[jondoeuk]

The company will host a virtual event on Wednesday, May 17th at 5:30 p.m. ET to discuss highlights from the presentation https://lifescievents.com/event/tscan/

[crazy horse 0]

SHORT 2023-05-09 21,279,941 36,487,718 58%

http://shortvolumes.com/?t=tcrx

[dinogreeves]

Incredible accomplishments, enough said. Double digit dollars coming here.

[crazy horse 0]

Baker Bros Holdings TSCAN THERAPEUTICS INC

TSCAN THERAPEUTICS INC COM 9,468 UNCH 2,784,792

https://www.nasdaq.com/market-activity/institutional-portfolio/baker-bros-advisors-lp-596248

[crazy horse 0]

Baker Brothers’ Philosophy and Strategy

Brothers Julian and Felix Baker have earned their guru status on Wall Street, having delivered an exceptional track record of annualized returns over the years. Julian has a business background from Harvard, while Felix has a Ph.D. in Immunology from Stanford.

Together, they have combined their individual expertise to generate superior returns by focusing solely on the biotech industry. Assets under management grew from $250 million in 2003, to $25.7 billion as of February 15th, 2023.

The fund’s strategy includes utilizing a fundamentally-driven way of investing to come up with its investment decisions, also known as “bottom-up investing”. Unlike top-down investing, which suggests studying the bigger picture of economic factors to make investment decisions, bottom-up investing involves looking at the company-specific fundamentals.

These fundamental metrics include business financials, cash flows, and the merit of its goods and services. This is crucial when investing in the biotech industry, as each company is very unique, requiring niche knowledge to understand its business model.

The fund’s philosophy stands in holding its investments ordinarily for three years, though its higher-conviction investments can be seen held for longer. Additionally, Baker Bros. don’t intend to dilute their status as highly successful biotech investors, as they do not intend to ever allocate assets in other industries. Still, some minor stakes in the industrial sector had been reported in the past.

Finally, the two brothers don’t believe in diversifying the fund’s portfolio. Instead, they emphasize that focusing on specific companies, which they can analyze and understand deeply and place concentrated positions in their securities, can generate superior returns over the long term.
https://www.suredividend.com/baker-brothers/

[dinogreeves]

Yup, this is shaping up for a possible squeeze......

[dinogreeves]

Yes, very good volume.

[crazy horse 0]

Good Volume

Yup, it is likely going to squeeze big, they want this higher

.

[dinogreeves]

Yup, it is likely going to squeeze big, they want this higher.

[IOUBLOKE1]

Weird trading like a boxing match

[crazy horse 0]

Quote, they have presentation on 17th,

7 Days away

As of yesterday it was higher than 23%, I really don't know, but I was going to compare the chart with LGV*N during that run, decided to skip it. My personal target is 6-8 dollars, it could go higher, I know one thing though, they have presentation on 17th, I also know Baker Brothers is top institutional holding and anything they touch turns into gold. I am sitting pretty with 6000 shares average 3.80, not going anywhere until my target is reached and we will get there, this has the making of a run to 15 dollars in short order.

[dinogreeves]

Also another huge catalyst is waiting on, once they get paid on that first installment from Amgen to the tune of 30 million dollars, it will run, two huge catalyst in a short window, I think those two will push the stock up for a double from here and add in the spice of higher than 23% short positions, it could go for a massive run with volume, that is why I want to compare it with LGV*N at some point to get a better understanding what is actually taking place.

[dinogreeves]

As of yesterday it was higher than 23%, I really don't know, but I was going to compare the chart with LGV*N during that run, decided to skip it. My personal target is 6-8 dollars, it could go higher, I know one thing though, they have presentation on 17th, I also know Baker Brothers is top institutional holding and anything they touch turns into gold. I am sitting pretty with 6000 shares average 3.80, not going anywhere until my target is reached and we will get there, this has the making of a run to 15 dollars in short order.

[IOUBLOKE1]

5% shorted ? Where will it squeeze.

[dinogreeves]

Crazy Horse, brother, I have been watching the pattern on this all morning, ripe for a massive short squeeze, the pattern and tape tells the story, one massive volume will take this thing for a double from here.

[crazy horse 0]

Appreciate your input

Sounds even better, now that you are in also. 7-8 is my first target, then 14-15, actually sooner that I thought, 3-4 months.

[dinogreeves]

The idea of TCRX running like LGV*N did just about 2-3 years ago, is definitely not out of the question if we get a ginormous short squeeze.